Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.
about
Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sitesEvaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design.Statins and breast cancer prognosis: evidence and opportunities.Mechanisms and assessment of statin-related muscular adverse effects.Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutionsAlcohol cirrhosis alters nuclear receptor and drug transporter expression in human liver.SLCO1B1 Polymorphisms and Statin-Induced Myopathy.The Promises of Quantitative Proteomics in Precision MedicineTransporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapyTransporter studies in drug development: experience to date and follow-up on decision trees from the International Transporter Consortium.Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin.Hepatic drug transporters: the journey so far.The role of organic anion transporting polypeptides in drug absorption, distribution, excretion and drug-drug interactions.Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam.Toward Prospective Prediction of Pharmacokinetics in OATP1B1 Genetic Variant Populations.Inhibition of Intestinal OATP2B1 by the Calcium Receptor Antagonist Ronacaleret Results in a Significant Drug-Drug Interaction by Causing a 2-Fold Decrease in Exposure of Rosuvastatin.In vitro assessment of the roles of drug transporters in the disposition and drug-drug interaction potential of olaparib.Rare Variants in the ABCG2 Promoter Modulate In Vivo Activity.Effect of CYP2C19 polymorphism on the pharmacokinetics of rosuvastatin in healthy Taiwanese subjects.
P2860
Q28478551-201B460A-FAC8-4B7D-8C27-3D84F3D9C921Q30582571-8428C94A-172C-42B8-B34A-0CA4806ADBCBQ34206487-2D575EC1-A9A1-4356-BB99-2C947452D78BQ34570995-66226A23-59D4-47CF-B8A7-D83DF7195C40Q35915932-07D2CA1E-1626-432F-977D-D230BDE3808CQ36776615-D9B02006-6A9F-41A5-9157-B94434B018ABQ37410969-FBF4E947-5D0D-4CDC-9D15-D60DD0C60422Q37647264-0C6CAE2F-ED5D-4F6D-AD25-F0F212A53404Q37735146-C64BCCB1-5558-4ABF-BCDA-C6533D18B984Q38099195-67E691CF-9488-414E-9F2B-50F785ABCF6CQ38155218-053BFBE8-6091-45A1-8239-FD2A42B0F2FDQ38560889-3AFC937D-ACDC-4D0A-A98B-783656B41545Q38991373-BFE0A75B-A5D2-4903-9AF2-CA016DC4602BQ41015337-CD648A5F-73B1-4446-9FF6-EBE415FBB916Q41706349-D24E08A1-B631-4C3A-9013-35DE50E815CFQ51396523-110142E6-250C-4A91-80CA-66E25F58CD89Q51450050-413E758C-1013-4D62-9E0B-D832E50AD643Q51749326-937E4D8A-0934-42E6-BCC0-003BE146D3DEQ54006194-4D33D33E-C33D-4907-8EB6-1B63E1A4F0B5
P2860
Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Impact of SLCO1B1 (OATP1B1) an ...... ering and myopathy of statins.
@en
Impact of SLCO1B1
@nl
type
label
Impact of SLCO1B1 (OATP1B1) an ...... ering and myopathy of statins.
@en
Impact of SLCO1B1
@nl
prefLabel
Impact of SLCO1B1 (OATP1B1) an ...... ering and myopathy of statins.
@en
Impact of SLCO1B1
@nl
P2093
P2860
P1433
P1476
Impact of SLCO1B1 (OATP1B1) an ...... ering and myopathy of statins.
@en
P2093
Fiorenza M Bonomo
Grant T Generaux
Kelly M Mahar Doan
Marta Johnson
P2860
P304
P356
10.3109/00498254.2011.562566
P407
P577
2011-03-22T00:00:00Z